Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Management of IHD
- Aims & objectives of management
- Non-pharmacological management of IHD
- Primary prevention of IHD
- Secondary prevention of IHD
- Non-pharmacological management: stable angina
- Non-pharmacological management: ACS & MI
- Stable angina: drugs to terminate/abort attacks
- Drugs used for chronic prophylaxis (1)
- Drugs used for chronic prophylaxis (2)
- Termination of an episode of angina
- Nitrates
- Nitrates - adverse effects/drug interactions
- Chronic prophylaxis of angina: beta blockers
- Calcium channel blockers (CCBs)
- Potassium channel openers
- Miscellaneous drugs in angina
- Drug treatment of myocardial infarction
- Treatment strategies: pre-hospital thrombolysis
- Treatment strategies: primary PCI
- Thrombolysis in myocardial infarction
- Drugs used in thrombolysis
- Thrombolytics – basic pharmacology
- Other drug based management of MI (1)
- Other drug based management of MI (2)
- Primary PCI and stenting (1)
- Primary PCI and stenting (2)
- Bare metal stents
- Drug eluting stents
- Complications of MI & management (1)
- Complications of MI & management (2)
- Complications of MI & management (3)
- Mechanical complications of MI
- Other complications
- Overall prognosis after MI
- Prevention of future attacks
- Conclusions (1)
- Conclusions (2)
- Conclusions (3)
- Conclusions (4)
- Final remarks
Topics Covered
- Management of IHD: aims and objectives
- Non-pharmacological and pharmacological management of IHD
- Acute MI: treatment strategies
- PCI and stenting
- Complications of MI & management
- Overall prognosis after MI
- Prevention of future attacks
Talk Citation
Lal, V. (2015, September 30). Ischemic heart disease 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/XNDG6957.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Vivek Lal has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Ischemic heart disease 2
Published on September 30, 2015
39 min
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:04
VIVEK LAL: Now that we have
understood the pathology
and the diagnosis of
ischemic heart disease,
let us come to a very important
aspect of this discussion.
And that is the management of IHD.
Let us first discuss
the aims and objectives
of the management of IHD.
Initially, let us discuss what
are the aims and objectives
of the management of stable angina?
The first and foremost thing
in the management of angina
is allaying the anxiety, or
reducing the anxiety of the patient.
This is very important because
there is a sympathetic discharge
whenever there is an angina.
The patient is anxious.
And he's having a sympathetic
discharge in the body.
This sympathetic
discharge in the body,
or in other words, a liberation of
catecholamine hormones in the body
can further aggravate the situation.
So it is essential that
the patient is calmed down
and his anxiety is reduced.
Then is the actual
management of angina
followed by the management
of any coexisting
disorders like diabetes
mellitus, and hypertension.
Apart from that, a reduction of
the risk factors and other advice
has to be given to the patient.
For example,
he should reduce his weight.
He should quit smoking.
He should control the
blood cholesterol levels.
And he should also
go for regular exercise.
1:24
Let us now discuss the aims
and objectives of the management
of acute coronary syndrome.
The first step in the management
of acute coronary syndrome
is to estimate the risk in unstable
angina or NSTEMI, or non-STEMI.
This is followed by a
reduction of anxiety,
as we have already discussed,
in the management of angina.
Then the relief of
pain is very important.
Because the pain can be very severe.
And it can contribute to
the anxiety of the patient.
Next step is to take the patient to
a specialized cardiac care center.
Because the definitive
management can
only be initiated in such a center.
This is followed by the
definitive management
of acute coronary syndrome
that is thrombolysis or dissolution
of the clot which is blocking
the coronary arteries,
or a percutaneous
coronary intervention called
a PCI or a placement of stent.
This we will discuss later on.
This is followed by a
supportive management
and monitoring the
prognosis of the patient.
In addition, early
management of complications
is a very important
step in the management
of acute coronary syndrome.
And also, a regular
follow up of the patient.